Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilofexor in NASH
NCT02854605Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of cilofexor in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events at 30 days and Percentage of Participants With Treatment-Emergent Laboratory Abnormalities at 30 days. Started Oct 2016; status: completed.
02
Drugs
cilofexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02854605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854605.